3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Stomach Neoplasms
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
30
Radiotherapy
21
Etoposide
9
Carboplatin
9
Bevacizumab
9
Cyclophosphamide
8
Vincristine
7
Radiation
7
Filgrastim
7
Cisplatin
7
Magnetic Resonance Spectroscopy
6
Irinotecan
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
etoposide phosphate
4
X-Rays
4
Specimen Handling
4
Phantoms, Imaging
4
Lomustine
4
Everolimus
4
selpercatinib
3
larotrectinib
3
Thalidomide
3
Paclitaxel
3
Nuclear Medicine Department, Hospital
3
Methotrexate
3
Erlotinib Hydrochloride
3
Chemotherapy, Adjuvant
3
Celecoxib
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Central Nervous System Neoplasms
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts